MOLLY DAVIS: Open Payments
NPI 1467114322 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,556 in 60 payments from 27 companies in 2025. Trend: 2023 $535 · 2024 $1,362 · 2025 $1,556
Food & beverage: $1,460Education: $96
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $160 |
| Novartis Pharmaceuticals Corporation | 6 | $149 |
| Janssen Biotech, Inc. | 5 | $130 |
| Daiichi Sankyo Inc. | 4 | $111 |
| ABBVIE INC. | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 4 | $98 |
| ARRAY BIOPHARMA INC | 4 | $96 |
| Stemline Therapeutics Inc. | 3 | $82 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $58 |
| Genentech USA, Inc. | 2 | $51 |
Products named: Trodelvy, Orserdu, PLUVICTO, Venclexta, Nubeqa, Enhertu, DATROWAY, XALKORI.
Industry payments across CO — which companies pay providers there.
